Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT06601192
- Locations
- 🇺🇸
ICON Early Phase, LLC, San Antonio, Texas, United States
🇺🇸ICON, Lenexa, Kansas, United States
A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT06589726
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Biogen
- Target Recruit Count
- 64
- Registration Number
- NCT06574828
- Locations
- 🇺🇸
Austin Clinic PPD, Austin, Texas, United States
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 690
- Registration Number
- NCT06441006
- Locations
- 🇲🇩
Institute of Phthisiopneumology Chiril Dragniuc, Chisinau, Moldova, Republic of
🇲🇳National Center for Communicable Diseases, Ulaanbaatar, Mongolia
🇵🇪Hospital Nacional Hipólito Unanue, Lima, Peru
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 128
- Registration Number
- NCT06441318
- Locations
- 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT06411860
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Limited - Leeds, Leeds, United Kingdom
A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06379867
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, China
A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 120
- Registration Number
- NCT06258265
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pimpri, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT06215521
- Locations
- 🇺🇸
Covance Clinical Research Unit 1341 Mockingbird Lane, Dallas, Texas, United States
🇺🇸Covance Clinical Research Unit 3402 Kinsman Blvd, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.